CSE Bulletin: Fundamental Change - FogChain Corp./Avisa Diagnostics Inc.

Avisa Diagnostics Inc., the issuer resulting from a Fundamental Change of FogChain Corp. (FOG.X), has been approved for listing.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

The Issuer offers an innovative approach to treating lung infections with rapid diagnostics to guide better clinical outcomes.

_________________________________

Avisa Diagnostics Inc., l'émetteur résultant d'un changement fondamental de FogChain Corp.(FOG.X), a été approuvé pour inscription.

Les documents de cotation et de divulgation seront disponibles sur www.thecse.com à la date de négociation.

L'émetteur propose une approche innovante pour traiter les infections pulmonaires avec des diagnostics rapides pour guider de meilleurs résultats cliniques.

Issuer/Émetteur: Avisa Diagnostics Inc.
Security Type/Titre: Common Shares/Actions ordinaires
Symbol(s)/Symbole(s): AVBT
Number of securities issued and outstanding/ Titres émis et en circulation: 41 219 310
Number of Securities reserved for issuance/ Titres réservés pour émission: 25 594 334
CSE Sector/Catégorie: Life Sciences/Sciences biologiques
CUSIP : 05380J 10 7
ISIN : CA 05380J 10 7 5
Old/Vieux CUSIP& ISIN: 34417N105/CA34417N1050
Boardlot/Quotité: 500
Consolidation: 1 New for 15 Old /1 nouveau pour 15 ancien
Trading Currency/Monnaie de négociation: CDN$/$CDN
Trading Date/Date de negociation: le 18 mai/May 2021
Other Exchanges/Autres marches: N/A
Fiscal Year end /Clôture de l'exercice financier: le 31 décembre/December
Transfer Agent/Agent des transferts: TSX Trust Company

 

The Exchange is accepting Market Maker applications for AVBT. Please email: Trading@theCSE.com

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com

Pour toute question, pour obtenir de l'information supplémentaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel à l'adresse: Listings@thecse.com

News Provided by Newsfile via QuoteMedia

The Conversation (0)

FogChain

FogChain Corp operates as a software as a service company. It provides a next-generation platform that seamlessly integrates application development and deployment that leverages a high-performance Fog based computing network to drive scale, and connects with the unique and ground-up built RadJav Blockchain. It operates in two segments namely Project development and Support and maintenance.

FogChain Corp operates as a software as a service company. It provides a next-generation platform that seamlessly integrates application development and deployment that leverages a high-performance Fog based computing network to drive scale, and connects with the unique and ground-up built RadJav Blockchain. It operates in two segments namely Project development and Support and maintenance. Keep Reading...
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned... Keep Reading...
Box of Moderna COVID-19 vaccine vials with red caps and labels.

Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine.The pharmaceuticals giant announced it has reached a global settlement with Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences GmbH over claims... Keep Reading...
Scientists examining a sample under a microscope in a lab setting.

Gilead to Acquire Arcellx in US$7.8 Billion Bet on Cancer Therapy

Gilead Sciences (NASDAQ:GILD) announced plans to acquire cancer immunotherapy partner Arcellx (NASDAQ:ACLX) in a deal worth up to US$7.8 billion, moving to take full control of their jointly developed multiple myeloma therapy anito-cel as it seeks to expand its oncology pipeline.The agreement,... Keep Reading...
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its second quarter of... Keep Reading...
Pill labeled "GLP-1" on a $100 bill background.

As GLP-1 Brands Go Prime Time, Regulators Flag Growing Illicit Market

At Super Bowl LX, companies behind blockbuster GLP-1 medications spent tens of millions of dollars to court a mass audience. But as brand-name makers and telehealth platforms race to normalize and expand access, regulators on both sides are warning of a parallel surge in counterfeit, compounded,... Keep Reading...
Solvonis Therapeutics

Expansion of SVN-015 into Depression Following Positive Preclinical Data

Demonstrates antidepressant-like activity benchmarked against fluoxetine (Prozac®), supporting potential in patients with inadequate SSRI response

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces the expansion of its investigational compound SVN-015 into the treatment of depression, supported by preclinical data... Keep Reading...

Interactive Chart

Latest Press Releases

Related News